ReviewVirulence2025
Decoding the role of gut mycobiota in immune regulation and disease.
Review in Virulence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Bifidobacterium animalis subsp. lactis and Enterococcus hirae Enhance Immunity by Modulating Gut Microbiota and Metabolic Pathways in Immunosuppressed Mice.Probiotics and antimicrobial proteins · 2026Article
- Dietary Inflammation, Gut Mycobiota, and Microbial Cross-Kingdom Associations with Cardiovascular Health in Older Adults.Metabolites · 2026Article
- The Gut Mycobiome in Inflammatory Bowel Disease: ReframingJournal of fungi (Basel, Switzerland) · 2026Review
- Article
- Dysbiosis of the Gut-Lung Axis and Its Immune Correlates During PulmonaryJournal of fungi (Basel, Switzerland) · 2026Article
- Diet, mycobiome and virome: from mucosal immunity to gut-brain axis regulation.Frontiers in nutrition · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The gut mycobiota, a minor but influential component of the microbiota, is increasingly recognized for its role in shaping host immunity and influencing health. Advances in sequencing technologies have now highlighted the diversity and complexity of these fungal communities. Dysbiosis of the gut mycobiota is associated with various diseases, including inflammatory bowel disease (IBD) and asthma, through mechanisms involving fungal-host interactions, immune modulation, and cross-reactivity. Despite these insights, the mechanisms underlying fungal-immune interactions remain incompletely understood. In this review, we explore the composition of the gut mycobiome and its role in health and disease, focusing on its interaction with the host immune system. We also explore the therapeutic potential of targeting the mycobiome to mitigate disease outcomes. By integrating recent findings, this review aims to deepen the understanding of fungal contributions to immune homoeostasis and modulating the mycobiome in the context of health and disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.